Welcome to our dedicated page for Marijuana news (Ticker: MAJI), a resource for investors and traders seeking the latest updates and insights on Marijuana stock.
MARIJUANA INC (OTCPINK: MAJI), doing business as Exousia Pro, Inc., generates a steady flow of news as a clinical-stage biotechnology company focused on exosome-based delivery systems, oncology, nutraceuticals, cannabinoids, diagnostics, and telehealth. Its announcements provide insight into how the company is advancing proprietary exosome technologies and structuring its business divisions.
News items frequently cover scientific and clinical milestones, such as the development of exosome-based therapies for malignant Glioma (Glioblastoma multiforme) and the receipt of Orphan Drug Designation from the FDA for this indication. The company also reports on technical advances like patent-pending methods for loading extracellular vesicles, successful loading of CBD into milk-derived exosomes, and planned Institutional Review Board studies to compare exosome-loaded CBD formulations with standard edibles.
Another recurring theme in MAJI news is product and market development. Exousia Pro has announced the launch of Maxasome™, an exosomal nutraceutical derived from Yellow Oyster Mushroom, and has described strategies to offer it on a subscription basis in the longevity and wellness market. The company also issues updates on licensing agreements with the University of Central Florida for exosome-based cancer diagnostics and therapies, including the planned NANOG DNA cancer screening test.
Corporate and strategic developments are also prominent in MAJI’s news feed. Releases describe the creation of the Exousia Health telehealth division, letters of intent and agreements to acquire telehealth platforms, and an all-stock transaction that gave MAJI a controlling interest in LAMY (LMMY) to advance Exousia AI as an SEC-reporting entity. Legal updates, such as court actions involving a former officer and related shareholders, appear as part of the company’s efforts to address governance and shareholder protections.
Investors and observers can use the MAJI news page to follow these scientific, commercial, licensing, telehealth, and corporate governance developments as the company reports them over time.
NexTel Medical (OTC: MAJI) detailed a new revenue-focused healthcare platform combining telehealth, diagnostics, and a large patient distribution network. Integrated acquisitions JumpstartRx and NueVistraMed generate about $135,000–$140,000 in monthly revenue, providing a non‑dilutive base.
The company plans to commercialize its patented Nanog saliva-based cancer screening test, with IRB clinical testing expected to begin shortly and a targeted launch as early as September–October 2026. A projected prescription-fulfillment program aims to process about 2,000 prescriptions per day at an estimated $4 per prescription.
NexTel Medical (OTC: MAJI) announced a first-of-its-kind exosome characterization study with Pennsylvania State University, led by Scientific Advisory Board members Dr. John Bitzer and Dr. Marvin Hausman. Using advanced mass spectrometry, the study maps bioactive compounds in proprietary mushroom-derived exosomes, informing new patent filings and product development.
Full study results are expected by end of June 2026 and are intended to support targeted formulations for NexTel’s telehealth platform and potential functional cosmetic and skincare applications.
NexTel Medical (OTCPK: MAJI) signed definitive agreements to acquire telehealth platforms JumpstartRx and NueVistraMed for $8 million ($2 million cash, $6 million preferred stock).
The deals add $135,000 in monthly recurring revenue, leverage a network of 1,500 online clinics and 350 facilities, and are intended to be non-dilutive to shareholders while accelerating Maxasome™ commercialization.
NexTel Medical Corp (OTCPK: MAJI) has begun the final stability phase for its first commercial exosome products, marking a shift toward revenue generation in 2026. Initial tests found no contamination by four key organisms. A successful 30-day stability readout could enable immediate launch within about 60 days.
NexTel is advancing a telehealth acquisition pipeline, has pivoted to a proprietary exosome-based method, plans to audit 2025–2026 financials starting July, and targets an OTCQB uplist in Q1 2027 as a fully SEC-reporting company.
NexTel Medical Corp (OTCPK: MAJI) announced the start of distribution of NANOG DNA cancer screening test kits the week of April 7, 2026 to collect control samples and validate against 100 dedicated test samples. The company said it holds a patent granted from a limited sample set and is expanding testing to broader cancer types.
The non-invasive assay uses a 2 ml saliva sample and standard PCR to measure exosomal NANOG DNA, aiming for universal multi-cancer screening with rapid, scalable processing as the firm advances toward commercialization.
Exousia Pro (OTCPK: MAJI) announced a litigation settlement dated March 16, 2026 that delivers immediate balance-sheet relief and reverses prior equity dilution. The company will pay $147,500 and, under GAAP, record cancellation of a $200,000 promissory note and return 6,297,511 common shares to treasury.
The transaction is expected to close within 30 days and is presented as improving audit readiness, strengthening liquidity, and enhancing EPS potential for current shareholders.
Exousia Pro (OTCPK: MAJI) announced cancellation of derivative securities convertible into 47 million common shares via a mediation and exchange that replaced Series B preferred conversion rights with 2 million LMMY shares and a lock-up agreement. The company is progressing toward Definitive Agreements to acquire three telehealth targets, one of which scaled monthly revenue from $80,000 to $135,000 and will be the exclusive supplier to 1,900 clinics with an anticipated 2,000 prescriptions/day at $4.00 per script. Management targets a $200,000–$300,000 Regulation A raise to fund launches and plans a buyback once funding goals are met. A mediation is scheduled for March 13, 2026. The company has filed to rebrand as Nextel Medical Corp.
Exousia Pro (OTCID: MAJI) announced a third Letter of Intent to acquire an established telehealth organization as part of a vertical integration strategy in healthcare.
The acquisition aims to provide direct-to-patient distribution for proprietary nutraceuticals and advanced cancer screening tests, reduce customer acquisition cost, and generate performance-based revenue (10% of hospital savings over four years).
Exousia Pro (OTCID:MAJI) executed a Letter of Intent to acquire a high-revenue telehealth platform and will operate it through new subsidiary Exousia Health.
The platform adds ~$80,000 monthly recurring revenue and an exclusive contract to supply testosterone across 1,900 clinics, starting February 2026, modeled to add $2.4 million in annual revenue based on 2,000 daily scripts over a 300-day year. Management projects $3.0 million net income for fiscal 2026 and intends to use the channel to sell Maxasome™ and future diagnostics.
Exousia Pro (OTCID:MAJI) announced on December 5, 2025 the market launch of Maxasome™, described as the first all-natural exosomal nutraceutical derived from 100% pure Exosome-Like Nanoparticles (ELNs) from Yellow Oyster Mushroom (Pleurotus citrinopileatus).
Maxasome™ is offered by monthly subscription at an estimated $200 for a 30-day supply and is positioned for telehealth and clinic partnerships targeting the longevity and wellness market that the company says spends over $100 million annually. The formulation claims a multi-modal biologically active payload including Ergothioneine, Beta-glucans, terpenoids, phenolics, and vitamin D2, and is available in sublingual, nasal, and enteric capsule delivery formats.